WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100720
Description: Pentostatin is classified as a purine analog, which is a type of antimetabolite. It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA. Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells. Pentostatin is used to treat hairy cell leukemia. It is given by intravenous infusion once every two weeks for three to six months. Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed. (Source: http://en.wikipedia.org/wiki/Pentostatin)
MedKoo Cat#: 100720
Chemical Formula: C11H16N4O4
Exact Mass: 268.11716
Molecular Weight: 268.27
Elemental Analysis: C, 49.25; H, 6.01; N, 20.88; O, 23.86
Synonym: CI825; CI-825; CI 825; PD81565; PD-81565; PD 81565; covidarabine; deoxycoformycin; pentostatine. brand name: Nipent.
IUPAC/Chemical Name: (R)-3-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
InChi Key: FPVKHBSQESCIEP-KDXUFGMBSA-N
InChi Code: InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9-/m0/s1
SMILES Code: O[C@H]1C2=C(N([C@H]3O[C@H](CO)[C@@H](O)C3)C=N2)N=CNC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 268.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Malfuson JV, Fagot T, Konopacki J, Souleau B, Cremades S, de Revel T. Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta Haematol. 2010;123(2):110-6. Epub 2009 Dec 24. Review. PubMed PMID: 20051682.
2: Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf. 2010 Jan;9(1):55-64. Review. PubMed PMID: 20001754.
3: Dasanu CA, Alexandrescu DT. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert Opin Pharmacother. 2010 Jan;11(1):41-50. Review. PubMed PMID: 20001428.
4: Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 2009 Oct;50 Suppl 1:32-7. Review. PubMed PMID: 19814696.
5: Grever MR, Zinzani PL. Long-term follow-up studies in hairy cell leukemia. Leuk Lymphoma. 2009 Oct;50 Suppl 1:23-6. Review. PubMed PMID: 19814694.
6: Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma. 2009 Oct;50 Suppl 1:18-22. Review. PubMed PMID: 19814693.
7: Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leuk Lymphoma. 2009 Oct;50 Suppl 1:12-7. Review. PubMed PMID: 19814692.
8: Dearden CE. T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S239-43. Review. PubMed PMID: 19778847.
9: Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2009 Jun;7(6):386-92. Review. PubMed PMID: 19606074.
10: Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15(17):1974-97. Review. PubMed PMID: 19519437.
Pentostatin is a purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
Pentostatin is used to treat hairy cell leukemia. It is given by intravenous infusion once every two weeks for three to six months. Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease. Pentostatin is also used in CLL patients who have relapsed.